Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology.

99 MANP has been recently investigated in hypertension and metabolic syndrome, where it showed a safe profile, a borderline significant blood pressure decline and a significant increase of cGMP and non-esterified fatty acids levels. 100 3.2.2 NEP inhibitors NEP (also known as neprilysin) is a membrane-bound metalloproteinase responsible for the breakdown of many vasoactive mediators, including NPs, but also glucagon, bradykinin, ox

also in 11,409 other papers